Drug Profile

A 02 - HangZhou Converd

Alternative Names: A02 - Hangzhou Converd

Latest Information Update: 28 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hangzhou Converd
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Gene transference; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in China
29 Mar 2019 Preclinical trials in Cancer in China before March 2019
29 Mar 2019 Pharmacodynamics data from a preclinical studies in Cancer presented at the 110^th Annual Meeting of the American Association for Cancer Research (AACR-2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com